HTE-DLP: An artificial intelligence system that improves the quality of lipid-lowering therapy

World Congress on Industrial Automation

July 20-22, 2015 San Francisco, USA

Alberto Zamora

Posters-Accepted Abstracts: Adv Robot Autom

Abstract :

HTE-DLP is an artificial intelligence software (CDSS) that performs a sequence of clinical decisions including all lipids lowering therapy and shows specific recommendations for each patient using efficiency, safety and cost criteria.It is based on European Guidelines for the Management of Dyslipidemia 2011.It is the first lipid-lowering therapyCDSSdevelopedin Spain andthe first tobe validatedin Europe. Methods: It was a cluster-randomized trial comparing standard prescriptions with HTE-DLP assistance, conducted by 10 expert physicians (7 specialists and 3 general practitioners) in cardiovascular risk management from five different hospitals and primary care centers in Catalonia (Spain). Each physician was asked to recruit 10 patients. The physicians enrolled consecutive eligible patients with high cardiovascular risk aged >18 years old with LDL-cholesterol (LDL-C) >100 mg/dl... Included patients were randomly distributed into the intervention or control group by a computer program. HTE-DLP was blocked automatically if a patient was assigned to the control group. Physicians usedHTE-DLP in the â�?�?real-clinic-worldâ�?. It was assessed the theoretical impact on the frequency of coronary artery disease with the CASSANDRA-REGICOR methodology. Researcherswereasked to evaluateHTE-DLP withquestionnaireQoEforapplicationsin health. Results:Use HTE-DLP meantadditional lowering ofLDL-C of20.5%.When expertsinvascular riskusingHTA-DLP numberofhigh vascular riskpatientsreachinglipidtargetsof LDL-C <70mg/dlincreased by4.4 times. Ingeneral practitioners would increase 5.8 times. Use ofHTE-DLP reduceddirect costsof lipid-loweringmedication, 19% lessper 1 mgofLDL-descended.The widespread use in Spain ofHTE-DLPwould mean in 2020a decrease incoronary heart diseasehealth costs between 4.7% and 6.4% (between 24 and 32 million Euros savings to the healthcare system). Physicians expressed good agreement with the 1st HTEDLP recommendation in 86.1% of cases and use was describedas comfortable in 85% of cases. Assessing users HTE-DLP by Questionnaire QoEfor applications in health was positive (3.89/5). Conclusion:Using in clinical practice a specific CDSS it is possible to improve the management of dyslipidemia with a decrease incoronary heart disease andloweringhealthcare costs.